Introduction: The efficacy and tolerability of Enzalutamide and Abiraterone Acetate have been reported in elderly patients with metastatic castration resistant prostate cancer (mCRPC). However, there is no randomized study directly comparing antitumor effects between these 2 agents in geriatric patients. We aimed to evaluate the efficacy of Enzalutamide (ENZA) and Abiraterone Acetate (AA) as a first-line treatment of mCRPC in elderly patients.
Materials and methods: The geriatric patients (
Results: One hundred thirty-four mCRPC patients (77 in AA, 57 in ENZA),
with a median age of 81 (75–93) were analyzed. The patient and disease
characteristics were similar between arms. While there were more grade 1–2
toxicities in AA arm (45.5% vs 17.5%, P = 0.001), the discontinuation
due to toxicity was similar between groups (8.5% vs 5.9%, P = 0.81).
The mOS was 18.0 months (95% CI, 15.2–20.7) in AA, and 20.0 months (95% CI,
4.4–35.5) in ENZA arm (P = 0.47). In multivariate analysis, high Gleason
Conclusion: In the first-line treatment of mCRPC in elderly (